Synaptogenix (TAOX) Competitors $8.36 +0.52 (+6.63%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock TAOX vs. ATYR, QNCX, CNTB, PLRX, IMMX, ORMP, CRDL, ADVM, BMEA, and SCLXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include aTyr Pharma (ATYR), Quince Therapeutics (QNCX), Connect Biopharma (CNTB), Pliant Therapeutics (PLRX), Immix Biopharma (IMMX), Oramed Pharmaceuticals (ORMP), Cardiol Therapeutics (CRDL), Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors aTyr Pharma Quince Therapeutics Connect Biopharma Pliant Therapeutics Immix Biopharma Oramed Pharmaceuticals Cardiol Therapeutics Adverum Biotechnologies Biomea Fusion Scilex aTyr Pharma (NASDAQ:ATYR) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation. Does the media refer more to ATYR or TAOX? In the previous week, aTyr Pharma had 31 more articles in the media than Synaptogenix. MarketBeat recorded 33 mentions for aTyr Pharma and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 beat aTyr Pharma's score of -0.15 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 3 Positive mention(s) 27 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ATYR or TAOX? Synaptogenix has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K414.46-$64.02M-$0.80-1.22SynaptogenixN/AN/A-$12.77M-$20.16-0.41 Do insiders and institutionals believe in ATYR or TAOX? 61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ATYR or TAOX? aTyr Pharma presently has a consensus target price of $23.25, indicating a potential upside of 2,290.01%. Given aTyr Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe aTyr Pharma is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, ATYR or TAOX? aTyr Pharma has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Is ATYR or TAOX more profitable? aTyr Pharma's return on equity of -93.69% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% Synaptogenix N/A -277.76%-150.79% SummaryaTyr Pharma beats Synaptogenix on 10 of the 14 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$27.36M$1.01B$2.53B$10.60BDividend YieldN/A4.84%2.49%4.86%P/E Ratio-0.411.2221.8528.46Price / SalesN/A29.59111.41128.87Price / CashN/A17.6342.0260.64Price / Book1.937.6933.246.53Net Income-$12.77M-$7.91M$6.87M$276.75M7 Day Performance8.01%-1.57%0.34%0.20%1 Month Performance46.92%23.49%-0.27%1.67%1 Year PerformanceN/A-14.91%95.09%32.73% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenix0.0649 of 5 stars$8.36+6.6%N/AN/A$27.36MN/A-0.414Gap UpATYRaTyr Pharma2.8815 of 5 stars$1.02+2.0%$23.25+2,179.4%-71.2%$99.95M$230K-1.2753Trending NewsQNCXQuince Therapeutics2.7881 of 5 stars$1.86-3.6%$8.14+337.8%+114.1%$99.91MN/A-1.7160CNTBConnect Biopharma2.8245 of 5 stars$1.73-5.5%$7.00+304.6%+27.5%$96.40M$26.03M0.00110PLRXPliant Therapeutics3.9819 of 5 stars$1.57-4.8%$8.19+421.5%-87.6%$96.38M$1.58M-0.4690News CoverageOptions VolumeIMMXImmix Biopharma2.7097 of 5 stars$2.87+6.3%$8.00+178.7%+87.3%$94.81MN/A-3.739ORMPOramed Pharmaceuticals0.2873 of 5 stars$2.23-1.8%N/A-3.4%$91.44M$2M-6.3710News CoverageCRDLCardiol Therapeutics1.7929 of 5 stars$1.03-1.0%$8.00+676.7%-36.4%$90.08MN/A-3.0320News CoverageADVMAdverum Biotechnologies3.5278 of 5 stars$4.29-5.9%$19.75+360.4%-47.8%$90.02M$1M-0.55190BMEABiomea Fusion3.5361 of 5 stars$1.51-5.0%$9.50+529.1%-87.4%$89.86MN/A-0.5050Gap UpSCLXScilex1.9274 of 5 stars$12.78-4.0%$437.50+3,323.3%-61.2%$88.89M$56.59M-0.4480Gap Up Related Companies and Tools Related Companies aTyr Pharma Alternatives Quince Therapeutics Alternatives Connect Biopharma Alternatives Pliant Therapeutics Alternatives Immix Biopharma Alternatives Oramed Pharmaceuticals Alternatives Cardiol Therapeutics Alternatives Adverum Biotechnologies Alternatives Biomea Fusion Alternatives Scilex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
